FDA identifies heparin contaminant

FDA to test all heparin at U.S. border
Heparin recalled by Japanese firms
Heparin safety concerns spread to Germany
Foreign substance found in Baxter heparin
Baxter recalls remaining heparin supply
Baxter was unaware plant not inspected
Baxter rival ramps up heparin output
Problem cited with some injectable heparin
Plant in China linked to troubled drug
U.S. supply of blood thinner at risk

WASHINGTON, March 20 (UPI) -- The U.S. Food and Drug Administration says the contaminant found in Baxter International (NYSE:BAX)'s heparin blood thinner is oversulfated chondroitin sulfate.

The agency says it is trying to determine if the substance, a dietary supplement derived from animals, was introduced in Baxter's China supply chain intentionally or by accident, the Chicago Tribune reported Wednesday.

Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, says the substance does not appear to have come straight from the pig intestines from which heparin is derived.

While chondroitin sulfate is a natural compound that occurs widely, the oversulfated version has not been widely studied.

The FDA says the substance almost certainly is derived from animal cartilage, the newspaper reported.

Science News

FDA identifies heparin contaminant